PSA Screening Likely Yields Reduction in Prostate Cancer-Specific Mortality

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 26, 2026.

via HealthDay

TUESDAY, May 26, 2026 -- Prostate-specific antigen (PSA) screening likely results in a reduction in prostate cancer-specific mortality, according to a review published online May 15 in the Cochrane Database of Systematic Reviews.

Juan V.A. Franco, M.D., Ph.D., from the Heinrich Heine University Düsseldorf in Germany, and colleagues examined the effects of prostate cancer screening versus no screening in men without a prior diagnosis of prostate cancer. Six randomized controlled trials, with 789,086 men aged 45 to 80 years, were included in the study.

The researchers found that screening based on PSA alone likely results in a reduction in prostate cancer-specific mortality (rate ratio, 0.87; 95 percent confidence interval, 0.80 to 0.95). This corresponds to two fewer deaths per 1,000 assuming a baseline risk of 16 prostate cancer-related deaths per 1,000. Based on an analysis including all eligible trials, screening may reduce overall mortality (rate ratio, 0.99; 95 percent confidence interval, 0.97 to 1.00). This corresponds to five fewer deaths assuming a baseline risk of 491 deaths from any cause per 1,000. Screening may result in little to no difference in adverse events (rate ratio, 1.32; 95 percent confidence interval, 0.48 to 3.65) and little to no difference in quality of life. There is likely an increase in prostate cancer diagnosis in association with screening, including localized (stage I and II) disease, but not advanced prostate cancer diagnosis.

"We want to be clear that this is not a blanket endorsement of universal screening," Franco said in a statement. "The decision should always be made between a patient and their doctor, with a full understanding of both the potential benefits and the very real risks of overdiagnosis and unnecessary treatment."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-27 03:04

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords